### Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 424B3

SPECTRUM PHARMACEUTICALS INC Form 424B3 November 22, 2006

Filed pursuant to rule 424(B)(3)

Registration Statement No. 333-115759

#### PROSPECTUS SUPPLEMENT NO. 2

(TO PROSPECTUS DATED SEPTEMBER 17, 2004)

#### **PROSPECTUS**

#### **UP TO 4,502,010 SHARES OF**

#### SPECTRUM PHARMACEUTICALS, INC.

#### COMMON STOCK

This prospectus supplement relates to the sale of up to 4,502,010 shares of our common stock by the selling stockholders named in this prospectus supplement no. 2, prospectus supplement no. 1 dated October 11, 2006 and the prospectus dated September 17, 2004 (the Prospectus). This prospectus supplement no. 2 should be read in conjunction with prospectus supplement no. 1 and the Prospectus.

The information appearing in the table below, as of the date hereof, supplements the information in the table appearing under the heading Selling Stockholders in the Prospectus, and, where the name of a selling stockholder identified in the table below also appears in the table in the Prospectus, the information set forth in the table below regarding that selling stockholder supersedes the information in the Prospectus. A selling stockholder named in the Prospectus transferred to the entity listed in the table below the securities, which are convertible or exercisable for the shares of our common stock listed in the table below.

	Shares of Common Stock			Shares of Common Stock  Beneficially Owned	
	Beneficially Owned  Number of Shares				
	Before	Offering % of	of Common Stock	Following th	ne Offering(3)
Name SDS Capital Group SPC, Ltd. (4) Xmark Opportunity Fund, L.P. (5)(6) Xmark Opportunity Fund, Ltd. (5)(6)	Number 1,882,509 503,654 763,305	Class(1)(2) 7.08% 1.97% 2.95%	Offered Hereby 22,750 38,871 66,130	Number 1,859,759 464,783 697,175	% of Class 6.99% 1.82% 2.70%

<sup>(1)</sup> For the purposes of calculating the percent of class beneficially owned by a selling stockholder, shares of common stock which may be issued to that selling stockholder within 60 days of November 22, 2006 are deemed to be outstanding.

<sup>(2)</sup> Pursuant to the terms of the warrant transferred to the selling stockholder, the number of shares of our common stock that may be acquired by the holder of the warrant upon any exercise of the warrant is limited to the extent necessary to insure that, following such exercise, the number of shares of our common stock then beneficially owned by such holder and any other persons or entities whose beneficial ownership of common stock would be aggregated with the holder s for purposes of the Securities and Exchange Act of 1934, as amended, does not exceed 4.99% of the total number of shares of our common stock then outstanding.

## Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 424B3

- (3) Assumes the sale by the selling stockholders of all of the shares of common stock available for resale under the prospectus.
- (4) SDS Management, LLC is the Investment Manager of SDS Capital Group SPC, Ltd. Steve Derby is the sole Managing Member of SDS Management, LLC, and is the natural person who exercises voting and investment control over the securities beneficially owned by SDS Capital Group SPC, Ltd. Each of SDS Management, LLC and Steve Derby disclaims beneficial ownership of the securities held by SDS Capital Group SPC, Ltd., except as to their pecuniary interest. SDS Capital Group SPC, Ltd. obtained the warrant shares from Sargon Capital International Fund, Ltd., a selling stockholder in the Prospectus.

# Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 424B3

(5)	All securities in the Company beneficially owned by Xmark Fund, L.P. and Xmark Fund, Ltd. were transferred (as of August 31, 2006) to their affiliates Xmark Opportunity Fund, L.P., a Delaware limited partnership, and Xmark Opportunity Fund, Ltd., a Cayman Islands exempted company.
(6)	Xmark Opportunity Partners, LLC (Opportunity Partners) is the sole member of the investment manager of Xmark Opportunity Fund, L.P., a Delaware limited partnership (Opportunity L.P.), and Xmark Opportunity Fund, Ltd., a Cayman Islands exempted company (Opportunity Ltd.), and, as such, possesses sole power to vote and direct the disposition of all securities of the Company held by Opportunity L.P. and Opportunity Ltd. David C. Cavalier and Mitchell D. Kaye, the Chief Operating Officer and Chief Executive Officer, respectively, of Xmark Capital Partners, LLC, the Managing Member of Opportunity Partners, share voting and investment power with respect to all securities beneficially owned by Opportunity Partners.
	ESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE RISK FACTORS BEGINNING ON PAGE 2 OF PROSPECTUS.
	her the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities of ed upon the accuracy or adequacy of the prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 22, 2006